Strongbridge Biopharmaâs primary focus has been to build its franchise around rare endocrine disorders, which includes product candidates for the treatment of endogenous Cushingâs syndrome and acromegaly, two rare diseases with a high unmet need for innovative treatment options. Given the well-identified and concentrated prescriber base addressing its target markets, the Company intends to use a small, focused sales force to market its products, if approved, in the United States, European Union and other key global markets. The Company intends to identify and in-license or acquire products or product candidates that would be complementary to its existing rare endocrine franchise or that would form the basis for new rare disease franchises.
Sector:
Health Technology
Industry:
Pharmaceuticals Major
Employees:
N/A
Frequently Asked Questions
What is Market Cap of Strongbridge Biopharma plc?
Market cap, also known as market capitalization, is the total market value of a company. It’s calculated by multiplying the current market price by the total number of shares outstanding. Strongbridge Biopharma plc market cap is $135.66M.
What is the 52-week high for Strongbridge Biopharma plc?
52 week high is the highest price of a stock in the past 52 weeks, or one year. Strongbridge Biopharma plc 52 week high is $4.26 as of September 07, 2025.
What is the 52-week low for Strongbridge Biopharma plc?
52 week low is the lowest price of a stock in the past 52 weeks, or one year. Strongbridge Biopharma plc 52 week low is $1.85 as of September 07, 2025.
What is Strongbridge Biopharma plc stock price today?
Strongbridge Biopharma plc stock price today is $2.00.
What was Strongbridge Biopharma plc stock price yesterday?
Strongbridge Biopharma plc stock price yesterday was $1.97.
What is the PE ratio of Strongbridge Biopharma plc?
The Price-to-Earnings (or P/E) ratio is a commonly used tool for valuing a company. It’s calculated by dividing the current share price by the earnings per share (or EPS). It can also be calculated by dividing the company’s Market Cap by the Net Profit. Strongbridge Biopharma plc’s P/E ratio is -3.31.
What is the Price-to-Book ratio of Strongbridge Biopharma plc?
The Price-to-Book (P/B) ratio is a commonly used tool for valuing a company. It’s calculated by dividing a company’s market capitalization by its book value. Strongbridge Biopharma plc P/B ratio is 3.0512.
What is the 50-day moving average of Strongbridge Biopharma plc?
The 50-day moving average is a frequently used data point by active investors and traders to understand the trend of a stock. It’s calculated by averaging the closing stock price over the previous 50 trading days. Strongbridge Biopharma plc 50-day moving average is $2.14.
